Incidence of antiretroviral therapy regimen modification and associated factors among People Living with HIV in Beijing, China
PLOS Global Public Health · 03.11.2025 · 5 (11) · e0005319
DOI: 10.1371/journal.pgph.0005319 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Global Public Health, online erschienen am 03.11.2025. Verfasst von Yuanqi Mi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Key R & D Program of China during the 14th Five-Year Plan Period, the National Natural Science Foundation of China, the Beijing Municipal Science & Technology Commission.
Abstract (Originalsprache)
Durability of the initially prescribed antiretroviral therapy (ART) regimen is critical for long-term virologic suppression among people living with human immunodeficiency virus (HIV). However, data on the incidence of regimen modification and its associated factors remain limited in China. We aim to quantify the incidence of initially prescribed ART modification and identify associated baseline factors in China. Treatment-naïve adults (≥18 years) who initiated ART with complete regimen records and have documented follow-up information in Beijing, China, from 2010 to 2020 were included. The primary outcome was initially prescribed ART regimen modification. A multivariable Cox proportional hazards model was applied to evaluate factors associated with modification risk. Of 18,911 participants included, 3,725 (19.7%) participants experienced ART modification over 472,565 person-months of follow-up (PMFU), a rate of 7.9 per 1,000 PMFU. The median follow-up was 32 (IQR 13–36) months. Modification rates peaked in months 0–6: TDF + AZT + NVP and LPV/r + 3TC + AZT exhibited the highest 6-month modification rates (59.4 and 57.7 per 1,000 PMFU, respectively), whereas TDF + 3TC + EFV, the most prescribed regimen, had the lowest early switch rate (8.8 per 1,000 PMFU). In multivariable analysis, baseline white blood cell (WBC) < 4.0 × 10⁹/L and WHO stage II–IV were associated with higher modification risk; missing baseline records of WBC, hepatitis B virus or hepatitis C virus coinfection, and later calendar year of ART initiation were associated with lower modification risk; compared to EFV + 3TC + TDF, LPV/r + 3TC + AZT had the highest modification risk. TDF + 3TC + EFV was the predominant initially prescribed regimen with the highest durability, while LPV/r + 3TC + AZT had the highest modification rate. These findings underscore the need for early ART initiation, comprehensive pretreatment screening, and enhanced early monitoring—especially during the first six months—to optimize regimen selection and minimize unnecessary modification.
Autor:innen und Institutionen
- Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America.
- School of International Organizations, Beijing Foreign Studies University, Beijing, China.
- Clinical Research Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
- Department of Epidemiology and Statistics, School of Public Health, Hebei Key Laboratory of Environment and Human Health, Hebei Medical University, Shijiazhuang, China.
- Vanke School of Public Health, Tsinghua University, Beijing, China.
- Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China.
ORCID-Profile: Yuanqi Mi, Xiaofei Wang, Mengge Zhou
Förderung
- the National Key R & D Program of China during the 14th Five-Year Plan Period
- the National Natural Science Foundation of China
- the Beijing Municipal Science & Technology Commission
- Incubation Fund of Vanke School of Public Health at Tsinghua University
- Sanming Project of Medicine in Shenzen Municipality
Zitieren
APA
Mi, Y., Wang, X., Zeng, Y., Guo, Y., Wang, P., Cheng, F., & Zhou, M. (2025). Incidence of antiretroviral therapy regimen modification and associated factors among People Living with HIV in Beijing, China. PLOS Global Public Health, 5(11), e0005319. https://doi.org/10.1371/journal.pgph.0005319
Vancouver
Mi Y, Wang X, Zeng Y, Guo Y, Wang P, Cheng F, et al. Incidence of antiretroviral therapy regimen modification and associated factors among People Living with HIV in Beijing, China. PLOS Global Public Health. 2025;5(11):e0005319. doi:10.1371/journal.pgph.0005319
BibTeX
@article{Mi2025,
author = {Mi, Yuanqi and Wang, Xiaofei and Zeng, Yuhong and Guo, Yang and Wang, Peicheng and Cheng, Feng and Zhou, Mengge},
title = {Incidence of antiretroviral therapy regimen modification and associated factors among People Living with HIV in Beijing, China},
journal = {PLOS Global Public Health},
year = {2025},
volume = {5},
number = {11},
pages = {e0005319},
doi = {10.1371/journal.pgph.0005319}
}
EUVIMED